IBBQ is a relatively new US biotech ETF that competes with established peers like IBB and XBI. Read why I don't recommend ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

Defendant Yisel Lopez has been found in contempt for violating an asset freeze order through the sale of property.

Gilead’s Kite Pharma is separating from its cell therapy joint venture with Fosun Pharma in China, handing Fosun the reins ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

20 January 2022 Gilead Sciences has sued an array of pharmaceutical suppliers and distributors accusing them of forming a ...

GC Therapeutics claims it can create off-the-shelf therapies from induced pluripotent stem cells faster and simpler than current methods.

Jackson Egen learned the value of basic lab research as a graduate student at UC Berkeley in the 90s while working under the ...

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.